MedTrace Logo

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

NCT05104463 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-01-23

Study results available
· View outcomes & findings →

Summary

This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.

Conditions

Interventions

DRUG

CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107

CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets

Sponsors & Collaborators

  • CuraSen Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · CuraSen Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2023-12-20
Completion
2024-02-01
FDA Drug
Yes

Countries

  • United States
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05104463 on ClinicalTrials.gov